We undertook an exclusive meta-analysis of cohort studies investigating the possible link between prenatal selective serotonin reuptake inhibitor (SSRI) exposure and autism spectrum disorders (ASD) in children to further investigate our previous suggestion of confounding by indication. The point estimates regarding the following cohorts were extracted and pooled: (1) pregnant women who discontinued SSRI until 3 months before pregnancy; (2) pregnant women who were exposed to SSRI during pregnancy; and (3) pregnant women with maternal psychiatric disorder but no exposure to SSRI during pregnancy. Although the pooled point estimate of the first cohort showed a trend for increase, it did not reach significance. The pooled point estimates of the latter cohorts showed a significant association with ASD which strengthens our previous suggestion of confounding by indication. Future studies should be adequately designed to differentiate whether the previously suggested association is a result of maternal psychiatric disorder or SSRI exposure or both.
Introduction
The question whether selective serotonin reuptake inhibitor (SSRI) use during pregnancy is associated with the risk of autism spectrum disorders (ASD) in children has been an increasing focus of research in the last decade [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . The statistically significant association between SSRI use during pregnancy and risk of ASD in children was demonstrated by several studies [1, 4, 10, 12 ], yet these results were challenged by the negative findings in some others [6, 9] , raising the possibility of confounding by indication, which is the term used when the clinical indication (e.g. depression) for choosing a treatment (e.g. SSRI) also affects the measured outcome (e.g. ASD) [19] . There is still no conclusive answer even after the publication to-date of eight case-control studies [1] [2] [3] [4] [5] [6] [7] [8] , five cohort studies [9] [10] [11] [12] [13] and five meta-analyses [14] [15] [16] [17] [18] .
In our recent previous meta-analysis of case-control studies, we demonstrated a significant association between SSRI exposure during the first (OR, 1.90; 95% CI 1.28-2.83), second (OR, 1.73; 95% CI 1.15-2.61) and anytime during pregnancy (OR, 1.66; 95% CI 1.23-2.23) and risk of ASD in children [17] . However, we also detected an unanticipated yet significant association with preconception-only SSRI exposure (use within the 3 months or 90 days prior to the last menstrual period (LMP) or estimated date of conception) with an effect size similar to the gestational exposure [17] . In addition, our qualitative review of the four cohort studies [9] [10] [11] [12] [13] yielded some inconsistent/negative findings, which further challenged and weakened the association that we detected in the meta-analysis of case-control studies. We suggested that a confounding by indication could not be ruled out [17] .
The objective of this short report is to explore this suggestion with a meta-analysis pooling exclusively cohort studies by including the recently published data by Malm et al. [13] . This time we would like to test our previous hypothesis of confounding by indication through assessing whether the combined point estimate regarding the risk of ASD in children would suggest an association among the following three separate cohorts of pregnant women enrolled in cohort studies [9] [10] [11] [12] [13] : (1) pregnant women who discontinued SSRI until 3 months before pregnancy; (2) pregnant women who were exposed to SSRI during pregnancy; and (3) pregnant women with maternal psychiatric disorder but no exposure to SSRI during pregnancy.
Methods

Search strategy
The search strategy was described previously [17] . However, because the previous search was conducted from inception to 26 December 2015, we ran an additional search from 26 December 2015 to 4 February 2017 using the same strategy [17] in PubMed/MedLine, Cochrane Central Register of Controlled Trials and Reprotox ® . No language or date restrictions were applied. The flow chart was prepared in accordance with Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) [20] and is presented in Figure 1 .
Inclusion and exclusion criteria
Because we previously combined the data from the casecontrol studies [17] , this time we only included the cohort studies investigating the link between prenatal exposure to SSRIs and ASD. A study was considered eligible if it met the following criteria: (1) a cohort of pregnant women with exposure to SSRIs any time during pregnancy was included; (2) a cohort of pregnant women who discontinued the SSRIs until 3 months before pregnancy or a cohort of pregnant women with maternal psychiatric disorder but no exposure to SSRIs during pregnancy was included; (3) a control (unexposed) group was included; (4) one of an odds ratio (OR), risk ratio (RR) or hazard ratio (HR) was reported; and (5) the data reported were not overlapping with another study. If an overlap between two studies was detected, the most recent one was included, after ensuring that both had similar methodological qualities. The exclusion criteria were case-control studies, case reports and series, animal studies, editorials and reviews.
Quality assessment
The Newcastle-Ottawa scale [21] was used for quality assessment of the study methodologies.
Outcome measures
The main outcome of interest for this meta-analysis was ASD.
Data extraction
Two authors (EK-A and SA) independently undertook the screening and data extraction process. The recently published data [13] were extracted using a standardized data extraction form and combined with our previously extracted data [17] and are presented in Table 1 . Any disagreements were resolved by consulting with another author (YCK).
Meta-analytic methods
Point estimates (adjusted when available) were extracted from eligible cohort studies and combined using generic inverse variance method and random-effects model in RevMan 5.3 (Review Manager 5.3; Cochrane Collaboration, Oxford, UK) [22] . Heterogeneity was assessed utilizing the Q and I-square statistic. An I-square value between 25% and 50% signified low heterogeneity, between 50% and 75% moderate heterogeneity and >75% signified high heterogeneity [23] . Publication bias was not assessed because the number of included studies was less than 10 [24] .
Results
Our search gleaned one additional cohort study by Malm et al. [13] published since our previous search. Because Boukhris et al. [12] did not report a point estimate consistent with our inclusion criteria, it was excluded. Four cohort studies were identified as eligible [9] [10] [11] 13] . The data from Hviid et al. [9] and Sorensen et al. [10] were largely overlapping. We chose to progress with Hviid et al. [9] in our primary analysis as it was methodologically superior and included an SSRI-discontinued group (use of SSRI starting from 2 years to 6 months before pregnancy) that is consistent with our inclusion criteria. However, we also extracted the point estimate of the SSRI-exposed group from the published data of Sorensen et al. [10] and retrieved the unpublished point estimate of the SSRI-discontinued group (use of SSRIs starting from 2 years to 6 months before pregnancy) from Sorensen et al. [10] through personal communication sensitivity analysis. Importantly, because El Marroun et al. did not measure and therefore did not provide an OR regarding ASD but did so regarding pervasive developmental problems (PDD), we extracted the OR regarding PDD (Model I) from this study [11] . Because the reported point estimates differed across the studies, the combined point estimates were reported either as HR, RR or OR with regard to the particular analysis.
Meta-analysis of cohort studies regarding SSRI-discontinuation until 3 months before pregnancy and risk of ASD in children
Three studies were eligible for this meta-analysis [9, 10, 13] . Hviid et al. [9] reported a cohort of pregnant women who discontinued SSRI until 6 months before pregnancy while Malm et al. [13] included a cohort of pregnant women who discontinued SSRI until 3 months before pregnancy. The discontinuation of SSRIs until 3 months before pregnancy was not significantly associated with an increased risk of ASD in Figure 1 PRISMA flow diagram Table 1 Characteristics of the cohort studies considered for this review children when adjusted point estimate from each study was pooled (aRR, 1.31; 95% CI 0.98-1.74). No significant heterogeneity was detected among the studies (P = 0.17, I-square = 46%) (Figure 2A ). The point estimate remained nonsignificant when Sorensen et al. [10] wsa included instead of Hviid et al. [9] with a non-significant moderate heterogeneity (aHR, 1.37; 95% CI 0.92-2.04; P = 0.051, I-square = 74%) ( Figure 2B ).
Meta-analysis of cohort studies regarding SSRI exposure during pregnancy and risk of ASD in children
Four studies were found eligible for this meta-analysis [9] [10] [11] 13] . The combined point estimate yielded a significant association between SSRI exposure during pregnancy and risk of ASD in children (aHR, 1.61; 95% CI 1.16-2.25). A low yet insignificant heterogeneity was detected among the studies (P = 0.15, I-square = 46%) ( Figure 3A) . The point estimate remained significant when Sorensen et al. [10] was included instead of Hviid et al. [9] (aHR, 1.65; 95% CI 1.28-2.11; P = 0.18, I-square = 41%, insignificant low heterogeneity) ( Figure 3B ).
Meta-analysis of cohort studies regarding maternal psychiatric disorder but no SSRI exposure during pregnancy and risk of ASD in children
Two studies were found eligible for this meta-analysis [11, 13] . We detected a significant association between maternal psychiatric disorder but no SSRI exposure during pregnancy and risk of ASD in children (aOR, 1.81; 95% CI 1.44-2.29). No significant heterogeneity was detected among the studies (P = 0.26, I-square = 20%) ( Figure 4 ). ****/**/*** ****/**/*_* ****/**/_** ****/**/*_* ****/**/*-* 
Discussion
In this meta-analysis, both SSRI exposure any time during pregnancy and maternal psychiatric disorder but no SSRI exposure during pregnancy was demonstrated to be significantly associated with the risk of ASD in children. Although the combined point estimate for SSRI discontinuation until 3 months before pregnancy indicated a small increase in the risk of ASD, the trend was not significant. The pooled effect size regarding SSRI exposure any time during pregnancy in this meta-analysis of cohort studies was very similar to the pooled effect size of SSRI exposure any time during pregnancy of the case-control studies we computed in our previous meta-analysis ( [16] . Nevertheless, Kobayashi et al. reported that this significant association did not persist when the analysis was restricted to the mothers with psychiatric disorders [16] , which is also corroborated by the significant association we detected between maternal psychiatric disorder but no SSRI exposure during pregnancy and the risk of ASD in children in our metaanalysis. Of interest, in our meta-analysis, the pooled effect size in maternal psychiatric disorder but no SSRI exposure cohort regarding ASD risk in children was slightly bigger than that of the pooled effect size in SSRI exposure during pregnancy cohort (aOR, 1.81 vs. 1.61) and the CI of both effects sizes were largely overlapping (1.44-2.29 vs. 1.16-2.25). Our meta-analysis provides some advantages over the meta- 
Figure 4
Meta-analysis of cohort studies regarding maternal psychiatric disorder but no SSRI exposure during pregnancy and risk of ASD in children. Forest plot of pooled adjusted odds ratios analysis by Kobayashi et al. [16] in terms of exclusively pooling cohort studies and comprising a recent cohort study [13] which was not available to them.
A combined summary of the findings of this and our previous meta-analysis [17] is as follows:
1. The pooled results of cohort studies in this meta-analysis suggest a trend for a mild increase in rişk of ASD with SSRI exposure until 3 months before pregnancy; however, it was not significant. 2. The pooled results of case-control studies suggest a significant association between preconception-only (within 3 months or 90 days prior to the LMP or estimated date of conception) SSRI exposure and risk of ASD in children [17] . 3. The pooled results of case-control studies suggest a significant association between SSRI exposure during first, second trimester and anytime during pregnancy and risk of ASD in children [17] , while pooled results of the cohort studies in this meta-analysis also suggest a significant moderate increase in risk of ASD with SSRI exposure at any time during pregnancy. The effect sizes were very similar. 4. The pooled results of the cohort studies in this study suggest a significant moderate increase in the risk of ASD with maternal psychiatric disorder but no exposure to SSRI during pregnancy with a slightly bigger effect size than that of SSRI exposure and with a largely overlapping confidence interval.
The most important limitation of our meta-analysis is the low number of included studies. Nevertheless, a major strength of our meta-analysis is the exclusive inclusion of cohort studies, which are less prone to bias in terms of assessing exposures during pregnancy. Our study is also the first metaanalysis to pool the point estimates of SSRI-discontinued and maternal psychiatric disorder but no SSRI exposure groups vs. SSRI exposure during pregnancy group.
In conclusion, this meta-analysis showed that maternal psychiatric disorder but no SSRI exposure is also associated with increased risk of ASD in children. The similar effect size of this group to that of SSRI exposure any time during pregnancy group with a largely overlapping confidence interval strengthens our previous suggestion that the maternal psychiatric disorder may be a strong confounder in studies assessing the connection between maternal SSRI use and ASD risk in children [17] . Although sought by an increasing number of studies and considered as biologically plausible [25] [26] [27] [28] [29] [30] , the suggested association of SSRI exposure during pregnancy and risk of ASD in children still remains to be adequately substantiated.
